Produktname:Pramlintide Acetate
Anderer Name:Amylin (Human),Symlin
CAS:196078-30-5
MF:C173H273N51O56S2
MW:4027.46
Abgeordneter:>175°C
Pramlintide acetate is an injectable human amylin analog that has been launched for the treatment of both type 1 and type 2 Diabetes, in conjunction with insulin. While it is also a 37-amino acid peptide, it differs from its parent predecessor by the substitution of Ala-25, Ser-28, and Ser-29 with prolines. Not only do these modifications improve the solubility of the peptide, they also eliminate the aggregation observed with amylin, resulting in a stable synthetic analog with retention of biological activity that is suitable for pharmaceutical use.
Symlin (pramlintide acetate) is a prescription medicine used to treat the symptoms of Type 1 and Type 2 Diabetes. Symlin may be used alone or with other medications.
Symlin belongs to a class of drugs called Antidiabetics, Amylinomimetics.It is not known if Symlin is safe and effective in children.
